While Krystal Biotech Inc has overperformed by 0.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KRYS fell by -12.60%, with highs and lows ranging from $219.34 to $133.22, whereas the simple moving average fell by -22.27% in the last 200 days.
On March 05, 2025, Jefferies started tracking Krystal Biotech Inc (NASDAQ: KRYS) recommending Buy. A report published by Citigroup on August 06, 2024, Downgraded its rating to ‘Neutral’ for KRYS. Goldman also rated KRYS shares as ‘Buy’, setting a target price of $160 on the company’s shares in an initiating report dated November 20, 2023. Cantor Fitzgerald Initiated an Overweight rating on October 24, 2023, and assigned a price target of $100. Citigroup initiated its ‘Buy’ rating for KRYS, as published in its report on October 12, 2023. Berenberg’s report from September 07, 2023 suggests a price prediction of $154 for KRYS shares, giving the stock a ‘Buy’ rating. Stifel also rated the stock as ‘Buy’.
Analysis of Krystal Biotech Inc (KRYS)
Further, the quarter-over-quarter increase in sales is 94.88%, showing a positive trend in the upcoming months.
Krystal Biotech Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 13.90% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.27, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and KRYS has an average volume of 319.36K. On a monthly basis, the volatility of the stock is set at 5.16%, whereas on a weekly basis, it is put at 5.11%, with a loss of -17.21% over the past seven days. Furthermore, long-term investors anticipate a median target price of $211.20, showing growth from the present price of $137.17, which can serve as yet another indication of whether KRYS is worth investing in or should be passed over.
How Do You Analyze Krystal Biotech Inc Shares?
Biotechnology giant Krystal Biotech Inc (KRYS) is based in the USA and is one of the largest companies in the market. When comparing Krystal Biotech Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 33.03, there is a growth in quarterly earnings of 3661.64%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 14.53%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.85% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
KRYS shares are owned by institutional investors to the tune of 91.85% at present.
